Name | Number of supported studies | Average coverage | |
---|---|---|---|
astrocyte | 19 studies | 63% ± 17% | |
oligodendrocyte precursor cell | 15 studies | 85% ± 13% | |
fibroblast | 10 studies | 34% ± 21% | |
GABAergic neuron | 9 studies | 44% ± 23% | |
adipocyte | 8 studies | 46% ± 13% | |
mesothelial cell | 8 studies | 48% ± 19% | |
smooth muscle cell | 7 studies | 34% ± 18% | |
endothelial cell | 6 studies | 29% ± 14% | |
cardiac muscle cell | 6 studies | 61% ± 23% | |
Mueller cell | 6 studies | 43% ± 18% | |
ciliated cell | 5 studies | 35% ± 12% | |
type II pneumocyte | 5 studies | 22% ± 6% | |
glutamatergic neuron | 4 studies | 28% ± 12% | |
epithelial cell | 4 studies | 33% ± 13% | |
erythrocyte | 4 studies | 58% ± 21% | |
pericyte | 4 studies | 25% ± 5% | |
interneuron | 4 studies | 55% ± 15% | |
cholangiocyte | 3 studies | 63% ± 11% | |
hepatic stellate cell | 3 studies | 41% ± 11% | |
differentiation-committed oligodendrocyte precursor | 3 studies | 80% ± 11% | |
GABAergic interneuron | 3 studies | 34% ± 13% | |
retinal pigment epithelial cell | 3 studies | 34% ± 17% | |
hepatocyte | 3 studies | 51% ± 16% | |
ependymal cell | 3 studies | 81% ± 9% | |
chondrocyte | 3 studies | 52% ± 27% | |
melanocyte | 3 studies | 44% ± 18% | |
basal cell | 3 studies | 46% ± 26% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 97% | 839.77 | 2563 / 2642 | 99% | 19.17 | 698 / 705 |
kidney | 100% | 1418.52 | 89 / 89 | 92% | 5.61 | 829 / 901 |
thymus | 99% | 582.24 | 648 / 653 | 77% | 1.85 | 464 / 605 |
pancreas | 100% | 858.34 | 328 / 328 | 72% | 1.86 | 129 / 178 |
skin | 71% | 689.39 | 1280 / 1809 | 77% | 6.57 | 363 / 472 |
liver | 96% | 732.60 | 217 / 226 | 43% | 1.30 | 175 / 406 |
esophagus | 84% | 478.69 | 1217 / 1445 | 55% | 1.50 | 100 / 183 |
lung | 88% | 319.17 | 509 / 578 | 40% | 1.21 | 461 / 1155 |
ovary | 64% | 256.36 | 115 / 180 | 61% | 1.84 | 261 / 430 |
intestine | 91% | 684.34 | 879 / 966 | 20% | 0.44 | 107 / 527 |
stomach | 81% | 311.52 | 289 / 359 | 27% | 0.68 | 77 / 286 |
adrenal gland | 89% | 371.76 | 230 / 258 | 13% | 0.29 | 29 / 230 |
eye | 0% | 0 | 0 / 0 | 100% | 25.20 | 80 / 80 |
muscle | 100% | 1964.48 | 801 / 803 | 0% | 0 | 0 / 0 |
heart | 97% | 703.41 | 832 / 861 | 0% | 0 | 0 / 0 |
bladder | 86% | 342.52 | 18 / 21 | 11% | 0.27 | 55 / 504 |
breast | 75% | 256.88 | 346 / 459 | 17% | 0.63 | 195 / 1118 |
uterus | 59% | 211.42 | 101 / 170 | 33% | 0.91 | 151 / 459 |
adipose | 92% | 552.62 | 1104 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 83% | 980.39 | 1107 / 1335 | 0% | 0 | 0 / 0 |
prostate | 58% | 177.62 | 141 / 245 | 3% | 0.07 | 17 / 502 |
tonsil | 0% | 0 | 0 / 0 | 60% | 2.03 | 27 / 45 |
spleen | 51% | 140.05 | 122 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 18% | 64.30 | 166 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0071560 | Biological process | cellular response to transforming growth factor beta stimulus |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0002062 | Biological process | chondrocyte differentiation |
GO_0021529 | Biological process | spinal cord oligodendrocyte cell differentiation |
GO_0032332 | Biological process | positive regulation of chondrocyte differentiation |
GO_2000741 | Biological process | positive regulation of mesenchymal stem cell differentiation |
GO_2000726 | Biological process | negative regulation of cardiac muscle cell differentiation |
GO_0045165 | Biological process | cell fate commitment |
GO_0006355 | Biological process | regulation of DNA-templated transcription |
GO_0007517 | Biological process | muscle organ development |
GO_0007417 | Biological process | central nervous system development |
GO_0007420 | Biological process | brain development |
GO_0001502 | Biological process | cartilage condensation |
GO_0051216 | Biological process | cartilage development |
GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
GO_0061036 | Biological process | positive regulation of cartilage development |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005737 | Cellular component | cytoplasm |
GO_0000785 | Cellular component | chromatin |
GO_0005634 | Cellular component | nucleus |
GO_0003677 | Molecular function | DNA binding |
GO_0042803 | Molecular function | protein homodimerization activity |
GO_0000978 | Molecular function | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
GO_0000981 | Molecular function | DNA-binding transcription factor activity, RNA polymerase II-specific |
GO_0000976 | Molecular function | transcription cis-regulatory region binding |
GO_0003700 | Molecular function | DNA-binding transcription factor activity |
GO_0001217 | Molecular function | DNA-binding transcription repressor activity |
GO_0005515 | Molecular function | protein binding |
Gene name | SOX6 |
Protein name | Transcription factor SOX-6 SRY-box transcription factor 6 Alternative protein SOX6 |
Synonyms | |
Description | FUNCTION: Transcription factor that plays a key role in several developmental processes, including neurogenesis, chondrocytes differentiation and cartilage formation (Probable). Specifically binds the 5'-AACAAT-3' DNA motif present in enhancers and super-enhancers and promotes expression of genes important for chondrogenesis. Required for overt chondrogenesis when condensed prechondrocytes differentiate into early stage chondrocytes: SOX5 and SOX6 cooperatively bind with SOX9 on active enhancers and super-enhancers associated with cartilage-specific genes, and thereby potentiate SOX9's ability to transactivate. Not involved in precartilaginous condensation, the first step in chondrogenesis, during which skeletal progenitors differentiate into prechondrocytes. Together with SOX5, required to form and maintain a pool of highly proliferating chondroblasts between epiphyses and metaphyses, to form columnar chondroblasts, delay chondrocyte prehypertrophy but promote hypertrophy, and to delay terminal differentiation of chondrocytes on contact with ossification fronts. Binds to the proximal promoter region of the myelin protein MPZ gene, and is thereby involved in the differentiation of oligodendroglia in the developing spinal tube. Binds to the gene promoter of MBP and acts as a transcriptional repressor (By similarity). . |
Accessions | ENST00000316399.10 [P35712-3] ENST00000396356.7 [P35712-3] ENST00000528252.5 [P35712-4] ENST00000529469.1 ENST00000527619.6 [P35712-4] P35712 E9PQ78 E9PQL4 E9PQ67 ENST00000533411.5 ENST00000528429.5 [P35712-1] ENST00000526673.1 L8EBC2 E9PN02 ENST00000683767.1 [P35712-1] ENST00000530378.5 ENST00000655819.1 [P35712-2] |